NEW YORK, NY / ACCESSWIRE / August 17, 2017 / While it was a good day for one Israeli company, it was a bad day for another. Israeli-based Teva saw its shares fall yesterday after a significant price target slash and rating cut from Citigroup. Shares of Pluristem soared after announcing a pilot study of the company will be initiated by the U.S. Department of Defense's Armed Forces Radiobiology Research Institute.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Limited
https://ub.rdinvesting.com/news/?ticker=TEVA

Pluristem Therapeutics Inc.
https://ub.rdinvesting.com/news/?ticker=PSTI

Teva Pharmaceutical Industries Limited's shares closed down 2.67% on Wednesday with nearly 25 million shares traded. Traders were less than enthused to find out that the Israeli-based generic drug maker had its rating cut from "buy" to "neutral" by Citigroup. The firm also significantly cut its price target from $32 to $19. The firm wrote, "We acknowledge we have been wrong." It was Teva's second quarter earnings results released earlier this month that made the firm realize it is a bad time to buy. Teva had cut its dividend by 75% in its earnings release and also cut its forecast for 2017. In other news the company also announced this week that it is looking to team up with other drug makers to fund some of its development pipeline as it struggles with debts and expiring patents. Company spokeswoman Denise Bradley wrote in an email to Reuters, "We are looking for partners ... a series of partners. It's not to fund the whole pipeline, just some projects in it. A small part of it."

Access RDI's Teva Pharmaceutical Industries Limited Research Report at:
https://ub.rdinvesting.com/news/?ticker=TEVA

Pluristem Therapeutics Inc.'s shares closed up 5.31% on Wednesday with a little over 1 million shares traded. This was a significant increase in trading volume as the stock's average volume is under 200,000 shares. The Israel-based leading developer of placenta-based cell therapy products announced yesterday that a pilot study of the company's PLX-R18 cell therapy will be initiated by the U.S. Department of Defense's (DOD) Armed Forces Radiobiology Research Institute (AFRRI), part of the Uniformed Services University of Health Sciences (USU). According to the company, the study will examine how effective PLX-R18 is as a treatment for Acute Radiation Syndrome (ARS) prior to, and within the first 24 hours of exposure to radiation. Co-CEO and Chairman Zami Aberman commented, "We are pleased to see increased interest from U.S. governmental agencies in our PLX-R18 cell therapy. In view of the therapeutic effects of our product and the current geopolitical situation, governments can potentially shield their citizens from the dire health effects arising from exposure to nuclear radiation, saving many lives in the process, which is our ultimate goal."

Access RDI's Pluristem Therapeutics Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=PSTI

Our Actionable Research on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Pluristem Therapeutics Inc. (NASDAQ: PSTI) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com